Crescent Biopharma
CBIO
35 hedge funds and large institutions have $15.8M invested in Crescent Biopharma in 2022 Q2 according to their latest regulatory filings, with 3 funds opening new positions, 4 increasing their positions, 13 reducing their positions, and 10 closing their positions.
0.02% less ownership
Funds ownership: 0.52% → 0.51% (-0.02%)
19% less funds holding
Funds holding: 43 → 35 (-8)
50% less capital invested
Capital invested by funds: $31.7M → $15.8M (-$15.9M)
69% less repeat investments, than reductions
Existing positions increased: 4 | Existing positions reduced: 13
70% less first-time investments, than exits
New positions opened: 3 | Existing positions closed: 10
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Renaissance Technologies
New York
|
+$70.9K |
| 2 |
Charles Schwab
San Francisco,
California
|
+$44.7K |
| 3 |
Vanguard Group
Malvern,
Pennsylvania
|
+$23.5K |
| 4 |
Millennium Management
New York
|
+$22.6K |
| 5 |
Jane Street
New York
|
+$14.2K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Dimensional Fund Advisors
Austin,
Texas
|
-$309K |
| 2 |
Federated Hermes
Pittsburgh,
Pennsylvania
|
-$157K |
| 3 |
Connor, Clark & Lunn Investment Management (CC&L)
Vancouver,
British Columbia, Canada
|
-$103K |
| 4 |
PVI
Pura Vida Investments
New York
|
-$100K |
| 5 |
BlackRock
New York
|
-$74K |
CBIO Hedge Fund Activity: Q2 2022 in Review
35 of the 5,959 institutional investors tracked by Wall St. Rank reported a position in Crescent Biopharma (CBIO) for Q2 2022, worth a combined $15.8M — down 50% from $31.7M a quarter earlier.
Sellers outnumbered buyers: 10 funds closed out of CBIO and 3 opened new positions — a net loss of 7 holders — while 13 trimmed existing stakes and 4 added.
The largest buyer was Renaissance Technologies, adding an estimated $70.9K. The largest seller was Dimensional Fund Advisors, exiting entirely with an estimated $309K sold.
- 35 institutional investors held Crescent Biopharma (CBIO) as of Q2 2022, down from 43 in Q1 2022.
- Funds reported $15.8M of Crescent Biopharma stock for Q2 2022, down 50% quarter-over-quarter.
- 3 funds opened new Crescent Biopharma positions in Q2 2022 and 10 closed out, a net change of -7 holders.
- The largest Crescent Biopharma buyer in Q2 2022 was Renaissance Technologies, an estimated $70.9K added.
- The largest Crescent Biopharma seller in Q2 2022 was Dimensional Fund Advisors, an estimated $309K sold.
Based on aggregated 13F filings for Q2 2022.